LENZ Therapeutics (Nasdaq: LENZ) will report Q4 and full year 2025 financial results and recent corporate highlights on Tuesday, March 24, 2026, via a live webcast and telephone conference.
The event begins at 8:30 a.m. EDT; a replay will be available on the company's investor website for 30 days.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – LENZ
+6.47%
16 alerts
+6.47%Session close to close
+3.0%Peak in 5 hr 49 min
$393.63MMarket Cap
0.8xRel. Volume
In the Mar 17 session, LENZ gained 6.47%, reflecting a notable positive market reaction.
Argus tracked a peak move of +3.0% during that session.
Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility.
The stock moved +6.5% in the session following this news. A strong positive reaction aligns with LEN...
Analysis
The stock moved +6.5% in the session following this news. A strong positive reaction aligns with LENZ’s pattern of favorable responses to commercial and partnership news, as seen after the consumer campaign and Middle East deal. However, prior selloffs on constructive regulatory and preliminary earnings updates suggest that enthusiasm has not been uniform. Investors watching an upside move could weigh execution on the upcoming March 24, 2026 report and ongoing commercialization metrics for VIZZ when assessing durability.
Exclusive Middle East commercialization deal for VIZZ with Lunatus and revenue share.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news has been mostly positive, but price reactions were mixed, with two notable selloffs on constructive regulatory and preliminary earnings updates.
Recent Company History
Over the past few months LENZ has focused on expanding VIZZ® globally and building its commercial franchise. Key milestones included an exclusive Middle East partnership on Jan 5, 2026, preliminary Q4 2025 results with initial VIZZ sales on Jan 7, 2026, and a high-profile U.S. consumer campaign on Jan 14, 2026. The Mar 10, 2026 EMA submission underscored ex‑U.S. growth aims. Today’s earnings-date announcement fits into this cadence of commercialization and regulatory execution.
"VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved"
Relating to the diagnosis, treatment and care of the eyes and vision, often involving medicines, surgical procedures, or medical devices used by eye specialists. Investors watch ophthalmologic developments because breakthroughs, safety results, regulatory approvals or new devices can open large, predictable markets much like a better, cheaper tool transforming an everyday job—affecting sales, pricing power, and long-term company value.
aceclidinemedical
"VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved"
Aceclidine is a medication that activates certain receptors in the eye to tighten the pupil and help open fluid drainage channels, which lowers pressure inside the eye and is used to treat glaucoma. Think of it as a tiny valve adjustment that helps fluid flow out more easily. For investors, developments around aceclidine—such as clinical trial results, regulatory approvals, or licensing—can affect the value and prospects of companies working on eye-care treatments.
presbyopiamedical
"eye drop for the treatment of presbyopia in adults, today announced that"
Presbyopia is the gradual loss of the eye’s ability to focus on close objects as the lens stiffens with age, causing tasks like reading or using a phone to require holding things farther away or using glasses. It matters to investors because it drives steady demand for corrective products and treatments—such as reading glasses, contact lenses, surgical procedures and emerging drugs—much like an aging population consistently needs new or replacement consumer goods and services.
FDA-approvedregulatory
"the first and only FDA-approved aceclidine-based eye drop for the treatment"
FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Tuesday, March 24, 2026, at 8:30 a.m. EDT to report its fourth quarter and full year 2025 financial results and recent corporate highlights.
To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 5138264. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.
About LENZ Therapeutics LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit www.VIZZ.com and www.LENZ-tx.com.
Contacts: Dan Chevallard LENZ Therapeutics IR@LENZ-Tx.com
FAQ
When will LENZ report Q4 and full year 2025 results and how can I join the March 24, 2026 call?
The report and call are on March 24, 2026 at 8:30 a.m. EDT. According to LENZ, join via live webcast on the LENZ investor site or dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) with code 5138264.
Where can investors access the LENZ (LENZ) live webcast for the March 24, 2026 results?
Investors can access the live webcast on the company's investor site at www.LENZ-tx.com. According to LENZ, the webcast is in the Investors & Media section and a replay will be posted for 30 days after the event.
Will LENZ provide a replay of the March 24, 2026 webcast and for how long will it be available?
Yes, a replay will be available for 30 days following the event. According to LENZ, the replay will be posted on its investor website for on-demand viewing after the live webcast concludes.
What topics will LENZ cover during the March 24, 2026 webcast for symbol LENZ?
LENZ will report its fourth quarter and full year 2025 financial results and recent corporate highlights. According to LENZ, management will discuss financial performance and recent company developments during the webcast and Q&A portion.
What phone numbers and access code do I use to join the LENZ March 24, 2026 conference call?
Dial (800) 715-9871 for domestic participants or (646) 307-1963 for international participants and enter access code 5138264. According to LENZ, those numbers and the code enable telephone participation in the earnings call.
Is the LENZ March 24, 2026 webcast relevant for investors following VIZZ aceclidine ophthalmic solution updates?
Yes, the webcast covers corporate highlights which may include updates on VIZZ and commercialization. According to LENZ, management will present recent corporate developments alongside the Q4 and full year 2025 financial results.
